Sionna Therapeutics [SION] vs Vertex [VRTX] Detailed Stock Comparison
Sionna Therapeutics
NASDAQ
Loading...
Vertex
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Sionna Therapeutics wins in 7 metrics, Vertex wins in 7 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Sionna Therapeutics | Vertex | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -16.51 | 28.19 | Sionna Therapeutics |
| Price-to-Book Ratio | 3.15 | 5.91 | Sionna Therapeutics |
| Debt-to-Equity Ratio | 2.75 | 8.89 | Sionna Therapeutics |
| PEG Ratio | 4.35 | -0.22 | Vertex |
| EV/EBITDA | -9.26 | 20.14 | Sionna Therapeutics |
| Profit Margin (TTM) | 0.00% | 31.86% | Vertex |
| Operating Margin (TTM) | 0.00% | 38.93% | Vertex |
| EBITDA Margin (TTM) | N/A | 38.93% | N/A |
| Return on Equity | 37.68% | 22.77% | Sionna Therapeutics |
| Return on Assets (TTM) | -33.21% | 13.09% | Vertex |
| Free Cash Flow (TTM) | $-52.81M | $-978.00M | Sionna Therapeutics |
| 1-Year Return | -4.00% | -15.36% | Sionna Therapeutics |
| Price-to-Sales Ratio (TTM) | N/A | 8.89 | N/A |
| Enterprise Value | $806.02M | $96.71B | Vertex |
| EV/Revenue Ratio | N/A | 8.47 | N/A |
| Gross Profit Margin (TTM) | N/A | 86.25% | N/A |
| Revenue per Share (TTM) | $0 | $44 | Vertex |
| Earnings per Share (Diluted) | $-1.72 | $14.05 | Vertex |
| Beta (Stock Volatility) | N/A | 0.44 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Sionna Therapeutics vs Vertex Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sionna Therapeutics | 4.08% | -2.52% | 36.91% | 49.72% | 45.63% | -4.00% |
| Vertex | -0.20% | 1.30% | 5.63% | -10.75% | -19.43% | -2.38% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sionna Therapeutics | -4.00% | -4.00% | -4.00% | -4.00% | -4.00% | -4.00% |
| Vertex | -15.36% | 35.61% | 53.56% | 195.48% | 986.15% | 2,043.51% |
Performance & Financial Health Analysis: Sionna Therapeutics vs Vertex
| Metric | SION | VRTX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.12B | $101.56B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 229,087 | 1,455,061 |
| 90 Day Avg. Volume | 193,736 | 2,174,740 |
| Last Close | $24.00 | $396.12 |
| 52 Week Range | $7.26 - $26.50 | $362.50 - $519.88 |
| % from 52W High | -9.43% | -23.81% |
| All-Time High | $26.50 (Aug 28, 2025) | $519.88 (Nov 04, 2024) |
| % from All-Time High | -9.43% | -23.81% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.12% |
| Quarterly Earnings Growth | N/A | 0.12% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.32% |
| Operating Margin (TTM) | 0.00% | 0.39% |
| Return on Equity (TTM) | 0.38% | 0.23% |
| Debt to Equity (MRQ) | 2.75 | 8.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $7.62 | $67.02 |
| Cash per Share (MRQ) | $5.95 | $24.90 |
| Operating Cash Flow (TTM) | $-63,908,000 | $3.85B |
| Levered Free Cash Flow (TTM) | $-61,688,000 | $2.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Sionna Therapeutics vs Vertex
| Metric | SION | VRTX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -16.51 | 28.19 |
| Forward P/E | -11.58 | 21.10 |
| PEG Ratio | 4.35 | -0.22 |
| Price to Sales (TTM) | N/A | 8.89 |
| Price to Book (MRQ) | 3.15 | 5.91 |
| Market Capitalization | ||
| Market Capitalization | $1.12B | $101.56B |
| Enterprise Value | $806.02M | $96.71B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 8.47 |
| Enterprise to EBITDA | -9.26 | 20.14 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.44 |
| Book Value per Share (MRQ) | $7.62 | $67.02 |
Financial Statements Comparison: Sionna Therapeutics vs Vertex
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SION | VRTX |
|---|---|---|
| Revenue/Sales | $0 | $2.96B |
| Cost of Goods Sold | N/A | $407.50M |
| Gross Profit | N/A | $2.56B |
| Research & Development | $13.67M | $978.40M |
| Operating Income (EBIT) | $-19.66M | $1.15B |
| EBITDA | $-19.23M | $1.34B |
| Pre-Tax Income | $-16.48M | $1.28B |
| Income Tax | N/A | $250.10M |
| Net Income (Profit) | $-16.48M | $1.03B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SION | VRTX |
|---|---|---|
| Cash & Equivalents | $82.70M | $4.67B |
| Total Current Assets | $273.68M | $10.01B |
| Total Current Liabilities | $9.53M | $3.78B |
| Long-Term Debt | $8.38M | $1.65B |
| Total Shareholders Equity | $351.77M | $16.50B |
| Retained Earnings | $-197.57M | $10.25B |
| Property, Plant & Equipment | $9.16M | $2.63B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SION | VRTX |
|---|---|---|
| Operating Cash Flow | $-10.71M | $404.90M |
| Capital Expenditures | $-86,000 | $-40.70M |
| Free Cash Flow | $-16.37M | $778.20M |
| Debt Repayment | N/A | $-1.30M |
| Common Stock Repurchase | N/A | $-696.60M |
Short Interest & Institutional Ownership Analysis
| Metric | SION | VRTX |
|---|---|---|
| Shares Short | 3.60M | 3.70M |
| Short Ratio | 22.40 | 1.72 |
| Short % of Float | 0.14% | 0.02% |
| Average Daily Volume (10 Day) | 229,087 | 1,455,061 |
| Average Daily Volume (90 Day) | 193,736 | 2,174,740 |
| Shares Outstanding | 42.44M | 256.94M |
| Float Shares | 11.04M | 255.58M |
| % Held by Insiders | 0.07% | 0.00% |
| % Held by Institutions | 0.98% | 0.98% |
Dividend Analysis & Yield Comparison: Sionna Therapeutics vs Vertex
| Metric | SION | VRTX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |